New drug cocktail shows promise for aggressive breast cancer
NCT ID NCT03090165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, ribociclib and bicalutamide, in people with advanced triple-negative breast cancer that has a specific marker (androgen receptor). The goal is to see if the combo can shrink tumors or stop them from growing. 37 participants are enrolled, and the study is not looking for a cure but for better disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michigan State University
Lansing, Michigan, 48910, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- New PET tracer could sharpen detection of aggressive breast cancer